Regulatory News
Monday, December 5, 2016
BRIEF-Onconova presents phase 2 data from oral Rigosertib and Azacitidine combination trial
* Onconova presents phase 2 data from oral Rigosertib and
Azacitidine combination trial in higher-risk myelodysplastic
syndromes (HR-MDS) at 2016 ASH annual meeting
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment